SecBot SecBot
8-K ·Filed Jul 10, 2026

INM

InMed Pharmaceuticals Inc.
BEARISH
Impact 6/10
Horizonmonths Processed4mo ago SEC0001213900-26-077127
8-K material event: Items 1.01
Actionable Insight ▼ Bearish

The reverse merger will likely result in massive dilution for current INM holders, with the combined company effectively a Mentari entity at a $125M valuation. Traders should monitor the S-4 for the exchange ratio and the special meeting date. The stock may trade down as the dilutive structure becomes clear, though near-term volatility could arise from the reverse split and PIPE speculation.

DirectionBearish
Confidencehigh
Horizonmonths

Drugs in focus

INM drug pipeline →

MT-001

● Neutral Named in this 8-K
Impact
Phase
Preclinical (IND-enabling)
Time to market
Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
Next catalyst
None dated

What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.57
T+0 close · Jul 10, 2026 · via day close
Latest settled
−15.29%
T+60 · $1.33
Vs SPY
−19.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $1.57entry
  2. T+1 · 4mo ago −0.64%α −0.99% · $1.56
  3. T+5 · 4mo ago −3.18%α −2.40% · $1.52
  4. T+20 · 3mo ago −10.19%α −13.38% · $1.41
  5. T+60 · 6w ago −15.29%α −19.28% · $1.33
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

InMed Pharmaceuticals entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics, clarifying deal sequencing, tax treatment, and the impact of pre-closing financing on the exchange ratio. The company also filed an S-4 registration statement for the all-stock reverse merger, expected to close in Q4 2026. The transaction effectively transforms InMed into a migraine-focused biotech (Mentari) with a $125M enterprise value for Mentari, but InMed's current shareholders face massive dilution and a reverse stock split to maintain Nasdaq listing.

Key Financial Metrics

Deal Value
$125.0M
Deal Type
merger

Key Facts

  • InMed (INM, $5M market cap) entered into Amendment No. 1 to merge with private biotech Mentari Therapeutics in an all-stock reverse merger.
  • Mentari's equity value is set at $125,000,000, implying extreme dilution for current INM shareholders relative to the $5M market cap.
  • The amendment introduces a 'Company PIPE Amendment' to allow additional pre-closing financing, which will further dilute the exchange ratio for INM holders.
  • A Nasdaq Reverse Split is planned before closing to maintain listing compliance.
  • InMed will redomesticate from British Columbia to Nevada and rename to 'Mentari Therapeutics, Inc.' at closing.
  • The S-4 registration statement was filed July 2, 2026, but has not yet been declared effective.
  • Closing expected in Q4 2026, subject to shareholder approvals for both companies and SEC effectiveness.

Financial Impact

Mentari's equity value is $125M vs. InMed's current market cap of $5M. Existing INM shareholders will retain a minority stake after the reverse merger, with additional dilution possible from the PIPE amendment.

dilutionenterprise valueshare count

Risk Factors

  • Merger may not close if shareholder approvals or SEC effectiveness are not obtained.
  • Extreme dilution of INM common shares; current shareholders will own a tiny fraction of the combined company.
  • Nasdaq delisting risk if reverse split is not approved or executed in time.
  • Mentari's pipeline is preclinical/early clinical, no approved products or revenue.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-077127
Document: ea029728401ex2-2.htm0001213900-26-077127
Document: ea029728401ex99-1.htm0001213900-26-077127
Document: 0001213900-26-077127-index-headers.html0001213900-26-077127
Document: 0001213900-26-077127-index.html0001213900-26-077127
Document: 0001213900-26-077127.txt0001213900-26-077127

US Market Status

Market Closed · Opens in 6h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 10, 2026